The Institute for Clinical and Economic Review (ICER) in a letter to the cystic fibrosis community says it supports fair prices that ensure patient access to key drugs.
ICER attempted to reassure the community that its position on Trikafta remained one that stresses the need for price negotiation, not non-coverage.
“Even though our report’s findings suggest that the price of Trikafta is set too high in relation to its clinical benefits, we certainly do not call for non-coverage as the answer,” ICER says in the letter. “We also feel confident that no insurer in the United States will even briefly entertain the option of non-covering Trikafta.”
To read the full letter on ICER’s website, click here.
